Geovax Labs, Inc. (GOVX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Geovax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies. Key programs include GEO-MVA (mpox/smallpox vaccine), Gedeptin (oncology therapy), and GEO-CM04S1 (COVID-19 vaccine). The company is classified as a non-accelerated filer and a smaller reporting company. As of May 14, 2026, 3,473,260 shares of common stock were issued and outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $1,636,863 |
| Net Loss | $(5,261,921) | $(5,357,651) |
| Loss Per Share (Basic/Diluted) | $(2.62) | $(11.20) |
| Cash and Cash Equivalents | $1,271,762 | $7,438,769 |
| Working Capital | $139,783 | $3,377,950 |
| Net Cash Used in Operating Activities | $(3,537,721) | $(5,965,680) |
| Net Cash Provided by Financing Activities | $1,723,742 | $7,914,402 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero from $1.64 million in Q1 2025 due to the termination of a government contract with BARDA in April 2025.
- Expense Reduction: Total operating expenses decreased by $1.77 million (25%) to $5.27 million. Research and Development (R&D) expenses fell by $1.45 million, and General and Administrative (G&A) expenses fell by $0.32 million, primarily due to the cessation of BARDA-related costs.
- Liquidity Deterioration: Cash reserves decreased by approximately $1.81 million during the quarter. Working capital declined significantly from $3.38 million to $0.14 million.
- Capital Raising: The company raised approximately $1.72 million in financing activities, including a registered direct offering in February 2026 and warrant exercise inducements in March 2026.
- Stock Split: A 1-for-25 reverse stock split was effected on January 9, 2026. All share and per-share data in this filing are retroactively restated.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Existing cash resources are projected to be sufficient only through June 2026.
- Capital Needs: The company plans to pursue additional funding through public/private equity, debt, or government grants. Failure to secure funding could force delays or termination of development programs.
- Development Milestones:
- GEO-MVA: Plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.
- Gedeptin: A Phase 2 trial in head and neck cancer is planned for initiation in the first half of 2027.
- GEO-CM04S1: Phase 2 trials are ongoing.
- Lease Commitments: The company's laboratory lease is set to end on September 30, 2026, due to facility closure plans by the landlord.
Investor Verification Checklist
- Cash Runway: Verify the timeline for securing additional capital to bridge the gap beyond June 2026.
- Dilution Risk: Review the impact of recent warrant exercises and the outstanding 5.37 million warrants on future share count.
- Revenue Pipeline: Assess the likelihood of securing new government contracts or commercial partnerships to replace the terminated BARDA revenue.
- Lease Obligations: Confirm plans for relocating laboratory operations following the September 2026 lease termination.
- Stock Split Impact: Ensure all historical comparisons account for the 1-for-25 reverse stock split.